The Oxford Vaccine Group has launched a novel clinical study, BIO-006, to investigate relapsing malaria infections caused by\u202fPlasmodium vivax. This unique parasite can remain dormant in the liver for months or years, reactivating to cause repeated malaria infections.
The Oxford Vaccine Group has launched a new clinical study, BiVISTA, to evaluate an experimental combination vaccine aimed at preventing enteric fever a disease caused by two different types of Salmonella bacteria, typhoid and paratyphoid.
A single dose of typhoid conjugate vaccine (TCV) offers safe, effective protection against typhoid two years after vaccination in all children, and sustained protection for older children at three to five years post immunisation, according to a report by researchers at the Oxford Vaccine Group and icddr,b. But it also shows a decline in protection at the later timepoints among children vaccinated at younger ages.
The Oxford Vaccine Group has released new footage of ground-breaking research aimed at revolutionising vaccine design, particularly for those most vulnerable to diseases like flu and COVID-19.
Professor Teresa Lambe OBE, Calleva Head of Immunology at the Oxford Vaccine Group, and Principal Investigator at the Pandemic Sciences Institute, has been elected a Fellow of the Academy of Medical Sciences, one of the most prestigious awards in the field.
Professor Sir Andrew Pollard, Director of the Oxford Vaccine Group at the Department of Paediatrics, and Ashall Professor of Infection and Immunity has today been elected a Fellow of the Royal Society.
A landmark study by scientists at the University of Oxford, has unveiled crucial insights into the way that COVID-19 vaccines mitigate severe illness in those who have been vaccinated.
Scientists at the University of Oxford and the University of Edinburgh have launched a pioneering study that examines how the immune system responds to repeated malaria infections. The BIO-004 study is being run in partnership between the Department of Biochemistry (Draper Lab, based in the Kavli Institute for Nanoscience Discovery), the University of Edinburgh (Spence Lab, Institute of Immunology and Infection Research) and the Oxford Vaccine Group (part of the Department of Paediatrics). BIO-004 will provide a unique insight into how the immune system adapts over the first few malaria infections of life, learning to tolerate malaria parasites and developing natural immunity to severe illness.
The Department of Paediatrics at the University of Oxford, has entered into an agreement with three Brazilian Universities, to contribute to the delivery of an undergraduate course in \u2018Translational Science\u2019, starting in 2024.
Researchers from the Department of Paediatrics today welcomed the Rt Hon Andrew Mitchell MP, Minister for Development and Africa, to the laboratories and clinics of several of its vaccine development groups.
Oxford Vaccine Group (OVG), which led the rapid clinical development of the Oxford vaccine in COVID-19 in the pandemic, has been awarded a total of \u00a37,788,783 by UK Aid for research into the prevention of five dangerous diseases with epidemic or pandemic potential.
Daniela Ferreira, Professor of Respiratory Infection and Vaccinology at the University of Oxford\u2019s Department of Paediatrics and the Department of Clinical Sciences at the Liverpool School of Tropical Medicine has been awarded one of six prestigious Research Professorships by the National Institute of Health and Care Research (NIHR).
The University of Oxford and the Coalition for Epidemic Preparedness Innovations (CEPI) today announced the launch of a new project to initiate early development of prototype vaccines against the Jun\u00edn virus, selected as an exemplar of the Arenavirus family which is responsible for multiple deadly haemorrhagic fevers with epidemic and pandemic potential.
A pioneering study into human immunity is being launched today by Oxford Vaccine Group at the University of Oxford. The study, called LEGACY03, is being funded by the Medical Research Council part of UK Research and Innovation. By investigating how lymph nodes work, and how they make responses to vaccines in younger and older people, it has the potential to improve vaccine design for different age groups significantly.
Researchers at the University of Oxford's Pandemic Sciences Institute have launched a new clinical trial to find a vaccine to protect people against Middle East Respiratory Syndrome (MERS).
A University of Oxford study has administered a new vaccine against tick-borne virus Crimean-Congo haemorrhagic fever (CCHF) to human volunteers for the first time. The clinical trial of the ChAdOx2 CCHF vaccine aims to confirm its safety and understand how individuals develop immunity following vaccination.
The University of Oxford and the Coalition for Epidemic Preparedness Innovations (CEPI) have entered into a strategic partnership to accelerate the development of safe, effective and globally accessible vaccines to counter the threat of future pandemics.
Researchers at the University of Oxford have launched a new mixed methods study to explore the acceptability of the Gonococcal Controlled Human Infection Model (GC-CHIM) in UK men.
![\"\"](\"https://www.ovg.ox.ac.uk/news/oxford-vaccine-group-launches-novel-study-on-relapsing-malaria/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n